, Tracking Stock Market Picks
Enter Symbol:
Dusa Pharmaceuticals, Inc. (DUSA) [hlAlert]

up 240.42 %

Dusa Pharmaceuticals, Inc. (DUSA) rated Buy with price target $4 by Roth Capital

Posted on: Wednesday,  Mar 31, 2010  9:25 AM ET by Roth Capital

Roth Capital rated Buy Dusa Pharmaceuticals, Inc. (NASDAQ: DUSA) on 03/31/2010. Previously Roth Capital rated Buy Dusa Pharmaceuticals, Inc. (NASDAQ: DUSA) on
08/07/2007., when the stock price was $2.35. Since then, Dusa Pharmaceuticals, Inc. has gained 240.43% as of 12/20/2013's recent price of $8.00.
If you would have followed the previous Roth Capital's recommendation on DUSA, you would have gained 240.42% of your investment in 2327 days.

DUSA Pharmaceuticals, Inc. is a pharmaceutical company developing drugs in combination with light devices to treat or detect a variety of conditions in processes known as photodynamic therapy or photodetection. They are engaged primarily in the research and development of our first drug, the Levulan brand of aminolevulinic acid HCl with light, for use in a broad range of medical conditions.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/31/2010 9:25 AM Buy
1.78 4.00
as of 12/31/2010
1 Week up  14.91 %
1 Month up  15.38 %
3 Months up  16.32 %
1 YTD up  83.87 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/21/2008 8:25 AM Buy
1.79 3.15
10/30/2007 9:25 AM Buy
2.38 5.00
10/4/2007 9:25 AM Buy
2.70 4.00
8/7/2007 3:25 PM Buy
2.35 3.40

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy